{"filings":[{"id":1138322,"accession_number":"0001808805-26-000027","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2026-06-18T20:05:43+00:00","items":["5.07"],"status":"ready","headline":"Nautilus Biotechnology stockholders elect directors, ratify auditor, approve say-on-pay at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Parag Mallick and Farzad Nazem as Class II directors with ~97% of votes cast (excluding broker non-votes).","Ratified PricewaterhouseCoopers LLP as independent auditor for FY2026 with 84,937,704 votes for, 27,748 against.","Advisory say-on-pay approved with 69,994,022 votes for, 268,341 against; broker non-votes 14,708,618.","Stockholders favored a 1-year frequency for future say-on-pay votes (69,142,818 votes for 1-year).","Company will hold say-on-pay votes annually until at least the 2032 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95646,"accession_number":"0001808805-26-000015","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nautilus Biotechnology Q1 loss narrows to $14.7M; cash $143.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $14.7M vs $16.6M in Q1 2025; operating expenses down 14% YoY to $16.1M.","Cash, equivalents, and investments total $143.4M as of March 31, 2026.","Launched Iterative Mapping Early Access Program; Baylor College of Medicine first customer for Tau proteoform assay in NIH-funded cancer study.","Appointed Amber Faust as VP of Global Sales, a commercial leader from Olink and SomaLogic."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108845,"accession_number":"0001808805-26-000004","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nautilus Biotechnology FY2025 net loss narrows to $59M; cash $156M; guidance for higher 2026 spend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss of $13.8M vs $17.6M YoY; operating expenses down 23% to $15.4M.","FY2025 net loss of $59.0M vs $70.8M in FY2024; operating expenses fell 18% to $66.8M.","Cash and investments $156.1M as of Dec 31, 2025; management sees sufficient runway through 2027.","Early Access Program launched Jan 2026 for Tau proteoforms; no material revenue expected in FY2026.","FY2026 operating expenses expected to increase 15-20% YoY; full commercial launch targeted late 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125305,"accession_number":"0001808805-25-000082","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nautilus regains Nasdaq minimum bid price compliance; deficiency closed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received notice on Nov 3, 2025 that closing bid price met $1 for 10 consecutive days.","Deficiency previously disclosed May 2, 2025; compliance period extended to April 27, 2026.","Company transferred to Nasdaq Capital Market on Oct 29, 2025 to utilize second compliance period.","Matter now closed; no further action required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125304,"accession_number":"0001808805-25-000077","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nautilus Biotechnology Q3 2025 net loss $13.6M; operating expenses down 19% to $15.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.6M for Q3 2025, improved from $16.4M loss in Q3 2024.","Operating expenses $15.5M, down 19% from $19.1M year-over-year.","Cash and investments $168.5M as of Sept 30, 2025.","Progress on Tau proteoform samples; early access program expected H1 2026; commercial launch late 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142021,"accession_number":"0001808805-25-000069","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nautilus Q2 net loss narrows to $15.0M; cash $179.5M; platform milestone","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Operating expenses $17.1M, down 18% YoY from $20.8M.","Net loss $15.0M improved from $18.0M loss in Q2 2024.","Cash, equivalents and investments $179.5M as of June 30, 2025.","Published first scientific manuscript validating Iterative Mapping method for proteoform measurement.","Signed two collaborations to study Tau proteoforms in Alzheimer's disease."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159989,"accession_number":"0001808805-25-000054","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nautilus Biotechnology elects Class I directors, ratifies PwC, reduces board size to 7","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Sujal Patel re-elected with 84.3M votes for; Matthew McIlwain elected with 82.2M votes for.","PricewaterhouseCoopers LLP ratified as auditor for 2025 with 99.5M votes for.","Board reduced from 9 to 7 directors effective after annual meeting.","Directors Vijay Pande and Michael Altman did not stand for re-election; McIlwain resigned as Class II to stand for Class I."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159988,"accession_number":"0001808805-25-000047","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2025-05-02T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nautilus Biotechnology receives Nasdaq bid price deficiency notice; has until Oct 28, 2025 to regain compliance.","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received notice on May 1, 2025 for failing to maintain $1.00 minimum bid price for 30 consecutive business days through April 30, 2025.","Has 180 calendar days (until October 28, 2025) to regain compliance; stock continues trading.","To cure, closing bid price must be at least $1.00 for ten consecutive business days during the Compliance Period.","If not compliant, may qualify for additional 180 days by transferring to Nasdaq Capital Market and meeting other requirements.","No immediate delisting; company evaluating options but no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159987,"accession_number":"0001808805-25-000039","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nautilus Q1 net loss $16.6M, operating expenses down 13% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $16.6M, improved from $18.7M in Q1 2024.","Operating expenses $18.8M, down 13% from $21.6M prior year.","Cash, equivalents, and investments $192.8M as of March 31, 2025.","CEO reports progress on Tau proteoform assay toward commercial launch."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178314,"accession_number":"0001808805-25-000004","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Nautilus Biotechnology reports Q4 net loss $17.6M; platform launch delayed to late 2026; headcount cut 16%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 operating expenses flat at $20.0M; FY2024 op. expenses $81.5M (+7% YoY).","Net loss Q4 $17.6M vs $17.0M YoY; FY2024 net loss $70.8M vs $63.7M YoY.","Proteome analysis platform commercial launch now expected late 2026 (previously undisclosed).","Headcount reduced ~16% to extend cash runway; cash $206.3M expected to fund operations through 2027.","Board changes: two directors not standing for re-election; Matthew McIlwain reclassified as Class I director; board size reduced to 7."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178313,"accession_number":"0001808805-25-000002","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2025-01-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Two Nautilus Biotechnology directors not standing for re-election at 2025 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Vijay Pande informed company on Jan 27, 2025, that he will not stand for re-election.","Michael Altman informed company on Jan 28, 2025, that he will not stand for re-election.","Both directors confirmed departure is not due to any disagreement with company operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194973,"accession_number":"0001808805-24-000070","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nautilus Q3 net loss $16.4M, cash $221.2M; OpEx flat YoY at $19.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $16.4M for Q3 2024, compared to $15.9M loss in Q3 2023.","Operating expenses $19.1M, flat YoY; personnel cost increase offset by incentive accrual reduction.","Cash, equivalents, and investments totaled $221.2M as of September 30, 2024.","CEO notes positive researcher feedback for single-molecule proteome platform, no revenue reported."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211267,"accession_number":"0001808805-24-000055","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nautilus Biotechnology reports Q2 2024 net loss of $18M, operating expenses up 9% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $18.0M in Q2 2024 vs $15.8M in Q2 2023.","Operating expenses of $20.8M, up $1.8M or 9% from $19.0M a year ago.","Cash, equivalents, and investments of $232.9M as of June 30, 2024.","Expense increase driven by higher headcount to support product development.","Company continues development of single-molecule proteome analysis platform."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229825,"accession_number":"0001808805-24-000043","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nautilus Biotechnology announces 2024 annual meeting voting results","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Melissa Epperly (92.1M for, 674K withheld), Matthew L. Posard (90.6M for, 2.1M withheld), Karen Akinsanya (89.9M for, 2.8M withheld) as Class III directors.","Ratified PricewaterhouseCoopers LLP as independent auditor for FY2024 with 105.1M votes for, 172.9K against, 69.2K abstentions.","Approximately 84% of outstanding shares (105.3M of 125.3M) represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229824,"accession_number":"0001808805-24-000038","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nautilus Q1 net loss $18.7M vs $15.0M YoY; cash $247.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $18.7M widened from $15.0M in Q1 2023; no revenue reported.","Operating expenses $21.6M, up 20% YoY on higher headcount for platform development.","Cash, equivalents and investments $247.7M as of March 31, 2024.","CEO cites progress on consumables, assay, instrument and software scale/reproducibility."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248304,"accession_number":"0001808805-24-000004","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nautilus Biotechnology reports FY2023 net loss $63.7M; cash runway into H2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $63.7M for FY2023, compared to $57.9M in FY2022; operating expenses $76.2M, up 20% YoY.","Cash, equivalents and investments $264.1M as of Dec 31, 2023; expected runway into second half 2026.","FY2024 operating expense expected to grow ~25% vs 2023.","Platform launch (instruments, consumables, software) planned for 2025.","CEO Sujal Patel cited fiscal discipline and progress on proprietary proteome analysis platform."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248303,"accession_number":"0001628280-24-007395","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Nautilus Biotechnology enters $125M at-the-market equity offering with TD Cowen","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sales agreement with TD Cowen to sell up to $125M of common stock via ATM program.","TD Cowen will receive up to 3.0% of gross proceeds as compensation.","Company may set sale parameters including price, volume, and timing; no obligation to sell.","Shares issued under S-3 registration statement filed Feb 28, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265796,"accession_number":"0001808805-23-000084","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2023-12-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nautilus Biotechnology files declaratory judgment suit against Somalogic and Caltech over patent non-infringement","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Filed suit on Dec 14, 2023 in Northern District of California against Somalogic and Caltech.","Seeks declaration that Nautilus does not infringe US Patent No. 7,842,793 related to DNA origami structures.","Somalogic alleged Nautilus' Proteome Analysis Platform infringes the '793 patent; Nautilus denies using any claimed technology.","Company states it has no plans to use the patent's technology in current or future products."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265795,"accession_number":"0001808805-23-000073","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2023-10-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nautilus Biotechnology Q3 net loss $15.9M, op ex up 21% YoY to $19.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $15.9M for Q3 2023 vs. $14.1M in Q3 2022.","Operating expenses rose 21% YoY to $19.1M, driven by increased headcount for product development.","Cash, cash equivalents and investments totaled $275.7M as of Sept. 30, 2023.","Company reiterates focus on commercial platform launch in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283019,"accession_number":"0001808805-23-000066","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nautilus Q2 net loss $15.8M; cash runway extended through 2025-2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Operating expenses $19.0M, up 23% YoY from $15.5M driven by product development headcount.","Net loss $15.8M vs $14.7M in Q2 2022; company pre-revenue, still in development stage.","Cash, equivalents, and investments $286.7M as of June 30, 2023; CEO says funds operations into 2026.","CEO reports progress integrating sample prep, probes, chips, instrument, and software for commercial launch."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302395,"accession_number":"0001808805-23-000050","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2023-06-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nautilus Biotechnology holds 2023 annual meeting; reelects three Class II directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders elected Parag Mallick, Matthew McIlwain, and Farzad Nazem as Class II directors with >92M votes for each.","Ratified PricewaterhouseCoopers LLP as independent auditor for FY2023 with 108.8M votes for, 299k against.","Approximately 109.2M shares represented out of 124.9M outstanding as of April 17, 2023.","No other business items or significant developments reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302394,"accession_number":"0001808805-23-000045","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2023-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nautilus Biotech Q1 net loss $15M, cash $302M; platform launch mid-2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $15.0M vs $15.8M year ago; operating expenses $18.1M, up 13% YoY on higher headcount.","Cash, equivalents and investments $302.0M as of March 31, 2023; runway expected into 2025.","Platform (instruments, reagents, software) launch planned for mid-2024.","Granted 4 new US patents in Q1, raising total to 12 granted patents.","Announced three winners of First Access Challenge for Early Access Program."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322051,"accession_number":"0001808805-23-000005","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2023-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nautilus Biotechnology reports FY2022 net loss of $57.9M; cash runway into 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $57.9M for FY2022 vs $50.3M in FY2021; operating expenses $63.6M, up 26%.","Cash, cash equivalents, and investments $313.6M as of Dec 31, 2022; runway into 2025.","Strategic partnership with TGen to study Nautilus platform for DIPG childhood cancer.","Opened San Diego office in University Town Center to expand geographic footprint.","Q4 2022 expenses below peak Q4 2021 levels, helping preserve cash."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340134,"accession_number":"0001808805-22-000107","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2022-11-01T23:59:59+00:00","items":["2.02","5.03","9.01"],"status":"ready","headline":"Nautilus Biotechnology Q3 2022 net loss $14.1M, cash $323.6M; bylaws amended","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Operating expenses $15.8M for Q3 2022, up 9% YoY from $14.6M.","Net loss $14.1M vs $14.5M in Q3 2021; no revenue (pre-revenue biotech).","Cash, cash equivalents and investments $323.6M as of Sept 30, 2022.","Company advanced platform development including commercial instrument readiness.","Bylaws amended to update stockholder nomination procedures and conform to DGLC."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340133,"accession_number":"0001808805-22-000108","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K/A","filed_at":"2022-11-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Nautilus appoints Karen Akinsanya to Nominating and Governance Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment effective October 27, 2022; committee now includes McIlwain (Chair), Pande, and Akinsanya.","Akinsanya joined the Board in March 2022; committee assignment was previously undetermined.","This amendment updates the original 8-K filed March 31, 2022 regarding Akinsanya's directorship."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357411,"accession_number":"0001808805-22-000079","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2022-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nautilus Q2 net loss $14.7M; cash $334.9M; platform launch on track for mid-2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Operating expenses of $15.5M in Q2 2022, down from $16.0M in Q1 2022.","Net loss of $14.7M for Q2 2022 vs. $10.7M in Q2 2021; cash, equivalents & investments $334.9M.","Platform launch (instruments and reagents) targeted for mid-2024; early access revenue starting early 2024.","Anticipates cash runway extending well into 2025.","Hired Eric Spence (VP Instrument Engineering) and Ken Kuhn (VP Reagent & Process Development)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376011,"accession_number":"0001808805-22-000059","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2022-06-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nautilus Biotechnology stockholders elect three Class I directors and ratify PwC as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sujal Patel, Vijay Pande, and Michael Altman elected as Class I directors with ~68.5M votes each.","Broker non-votes of 11,840,796 shares on director election.","Ratification of PricewaterhouseCoopers as independent auditor: 80.9M for, 31,871 against.","81,224,940 shares represented (65.3% of 124,456,653 outstanding shares)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376010,"accession_number":"0001808805-22-000044","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2022-05-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nautilus Biotechnology Q1 net loss widens to $15.8M on higher R&D and G&A costs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Operating expenses $16.0M, up 90% YoY from $8.4M, driven by headcount and public company costs.","Net loss $15.8M vs $8.4M in prior year; no revenue reported (pre-revenue proteomics platform).","Cash, cash equivalents, and investments $349.0M as of March 31, 2022.","Scientific progress: manuscript on single-molecule protein arrays, Genentech collaboration results, and AACR antibody data."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394344,"accession_number":"0001808805-22-000030","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2022-03-31T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Nautilus Biotechnology appoints Karen Akinsanya, Schrödinger President, to Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment effective March 30, 2022; Akinsanya will serve as Class III director through 2024.","Akinsanya is President of R&D, Therapeutics at Schrödinger and has 25+ years in drug discovery.","Director compensation: $40,000/year plus initial option award of 105,998 shares ($370K grant date FV).","She joins a board that includes leaders from genomics, cancer therapeutics, and tech (Illumina, Perceptive Advisors, etc.)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394343,"accession_number":"0001808805-22-000003","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2022-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nautilus Biotechnology reports FY2021 net loss of $50.3M; operating expenses up 221% to $50.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2021 net loss $50.3M, compared to $15.6M in 2020; operating expenses $50.5M, up 221%.","Cash, equivalents, investments $362.1M as of Dec 31, 2021; raised ~$345.5M via SPAC merger in June 2021.","Research collaborations with Amgen and MD Anderson; strategic partnership with Abcam for reagents.","Platform commercialization targeted by end of 2023; published PrISM proteomics approach."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":412932,"accession_number":"0001808805-21-000016","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2021-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nautilus Q3 net loss widens to $14.5M; OpEx up 262%; cash at $374M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $14.5M for Q3 2021 vs. $4.0M loss in Q3 2020.","Operating expenses $14.6M, up 262% YoY on higher headcount and public-company costs.","Cash, cash equivalents and investments totaled $374.0M at September 30, 2021.","Strategic partnership with Abcam and two new research collaborations (pharma and MD Anderson).","Published theoretical foundation for PrISM single-molecule protein identification method."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":431593,"accession_number":"0001808805-21-000004","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2021-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nautilus Biotechnology Q2 2021 net loss of $10.7M; raised $345.5M in business combination","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Completed business combination with ARYA Sciences, receiving gross proceeds of $345.5M.","Q2 2021 operating expenses $10.7M (up 215% YoY); net loss $10.7M vs $3.4M in Q2 2020.","Cash and investments $388.4M as of June 30, 2021.","Appointed Emma Lundberg, Ph.D. to Scientific Advisory Board.","Planning platform commercialization in late-2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}